Oikonomou · Cardiovascular research 2021 · multicenter observational cohort study · n=3912

Standardized measurement of coronary inflammation using cardiovascular computed tomography: integration in clinical care as a prognostic medical device.

Cited 100 times in the scientific literature.

Level 3 - non-randomized controlled study

Multicenter prognostic cohort study with external validation

PubMed 34450625 · doi:10.1093/cvr/cvab286 · record verified 2026-08-28

What was done

Researchers developed and validated CaRi-Heart®, an algorithm that integrates perivascular fat attenuation index (FAI) mapping (measuring coronary inflammation), clinical risk factors, and coronary computed tomography angiography (CCTA)-derived plaque metrics to predict 8-year fatal cardiac event risk. The study evaluated 3,912 consecutive patients undergoing clinical CCTA in the USA (n = 2,040, training cohort) and Europe (n = 1,872, external validation cohort).

What was found

The integrated risk model improved discrimination of 8-year fatal cardiac events compared with a clinical risk factor-based model alone, showing a Δ(C-statistic) of 0.085 (P = 0.01) in the US cohort and 0.149 (P < 0.001) in the European validation cohort. Decision curve analysis demonstrated consistent net clinical benefit across the cardiac risk spectrum.

Why it matters

This medical device provides a standardized, non-invasive method to quantify vascular inflammation from standard CCTA scans, substantially refining individual cardiovascular risk prognostication beyond standard clinical risk scores.

Limits

The abstract does not report baseline patient characteristics, specific fatal event rates, or absolute C-statistic baseline values. Additionally, it remains unproven in the provided data whether risk-guided management changes informed by this device improve long-term patient clinical outcomes.

Cited by